3 Biotech Stocks That Are Trending Pre-Market On Monday

CORAL GABLES, FL / ACCESSWIRE / October 2, 2017 / The biotech sector continues to show a positive momentum in the market over the last week as the Ultra Nasdaq Biotech Proshares (BIIB) has presented gains of 2.25%. If we look at it’s recent performance, we see that shares have gained 5.60% over the last month, 26.92% in the last 6 months and 29.3% over the last 12 months of trading. With that being said, here are three biotech stocks to pay close attention to during Monday’s (10/2/17) trading session.

GT Biopharma, Inc. (GTBP) a targeted immunotherapies company with a strong focus on treatments for Central Nervous System diseases is set to host a corporate update conference call Monday (10/2/17) at 4:15pm EST. The conference call will be with their management team, specifically, CEO Dr. Kathleen Clarence-Smith, CMO Dr. Raymond Urbanksi and Chairman Anthony Cataldo and they will be discussing the advancements made with their targeted immunotherapies that are currently in FDA clinical trials and its most recent CNS drug acquisition.

Shareholders and interested parties are invested to participate in the call. The dial in number is 712-775-7031, and the meeting ID number is 576-591-822.

MannKind Corporation (NASDAQ: MNKD) is trending pre-market on Monday (10/2/17) as shares have gained 19% hitting pre-market highs of $2.44. This spike comes off the heels of the company announcing Monday morning that the FDA has approved an update to the Afrezza to include new clinical data regarding rapid onset of activity and duration of effect.

“Available data suggests approximately 70% of people living with diabetes on insulin are not at HbA1c goals of <7%,” said Michael Castagna, Chief Executive Officer, MannKind Corporation. “We firmly believe that in order for patients to achieve better HbA1c goals, control of mealtime glucose spikes is critical. This label update supports Afrezza as a unique fast-acting mealtime insulin that provides doctors and patients with the flexibility necessary to help them achieve glycemic control.”

Endocyte Inc. (ECYT) is a biopharmaceutical company that is focused on developing targeted therapeutics for personalized cancer treatments. The stock surged over 11% during pre-market trading on Monday following an announcement that the company completes an exclusive global license of phase 3 ready PSMA- targeted radioligand therapy for development for prostate cancer. (ECYT) reached pre-market highs of $1.60.

“This transaction is transformational to Endocyte, accelerating our path to commercialization. Lu-PSMA-617 has the potential to be the first-in-class RLT to address both bone and soft tissue disease, and it is profoundly important to the many patients suffering from mCRPC,” stated Mike Sherman, president and CEO of Endocyte.

BIOTECHSTOCKS

About BiotechStocks.com

BIOTECHSTOCKS,.com is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $800,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending Oct. 1, 2017 now extended to November 1st, 2017 to publicly disseminate information about (GTBP). Full Disclaimer Here.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither BTS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://biotechstocks.com.

NO WARRANTY

BTS, the Author and the Reviewer (collectively referred to as the “Publishers”) are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

Contact:

news@biotechstocks.com

SOURCE: BiotechStocks.com

ReleaseID: 476806